| Literature DB >> 20680154 |
Shakeel Ul Rehman1, A Syed Sameer, Lubna Zahoor, Nidda Syeed, Mahoor S Nanda, Adil Hafiz, Zaffar A Shah, Mushtaq A Siddiqi.
Abstract
Kangri cancer is a unique thermally-induced squamous cell carcinoma (SCC) of skin that develops due to persistent use of Kangri (a brazier), used by Kashmiri people, to combat the chilling cold during winter months. We designed a large scale case-control study to characterize the frequency of two polymorphisms within the MHC class III-linked HSP70genes, Hsp70-2 and Hsp70-hom, in order to find any association of these genotypic variants for predisposition to and clinical outcome of Kangri cancer patients from Kashmir valley in North India. Polymerase Chain Reaction and restriction enzymes were utilized to characterize the frequency of two polymorphisms with in Hsp70-2 and Hsp70-hom genes in 118 Kangri carcinoma cases and 95 healthy controls from the same population of Kashmir. Association of high frequency allelic variants of Hsp70genes with various clinicopathological features of prognostic significance was assessed by Chi-square test using SPSS software. In this study, allelic frequency of Hsp70-2 A/G heterozygote (0.87) (P = 0.012) was found to be significantly high in Kangri cancer cases compared to control (0.736) with a Relative Risk of 2.45 fold. Conversely, the allelic frequency of Hsp70-2 A/A allele in homozygous condition was significantly low in Kangri cancer cases and worked out to be 0.084 (Vs 0.252 in control) with P is equal to 0.001, implicating it as a protective allele against Kangri cancer in subjects with this genotype. Similarly, significantly high frequency of 0.50 (Vs 0.29 in control) of Hsp70-homC/C allele was found in homozygous condition in Kangri cancer cases suggestive of a positive relative risk associated with this genotype (RR is equal to 2.47) (P is equal to 0.002). The overall allele frequency data analysis of Hsp70-2 and Hsp70-hom genes was significant (chi(2) is equal to 12.38, P is equal to 0.002; and chi(2) is equal to 12.21, P is equal to 0.002). The study also reveals considerable association of high frequency alleles of HSP70 genes, especially of Hsp70-2 A/G or G/G in Kangri tumors with clinico-pathological features of poor prognosis. These results indicate that the relative risk of Kangri cancer associated with Hsp70-2 and Hsp70- hom gene polymorphisms is confined to Hsp70-2 A/G or G/G and Hsp70homC/C haplotype in our population. The study, therefore, suggests Hsp70-2 A/G or G/G and Hsp70homC/C genotypes as potential susceptibility markers and independent prognostic indicators in Kangri carcinoma patients in Kashmiri population.Entities:
Keywords: HSPs; Kangri cancer; Kashmir; RFLP; mutation
Year: 2009 PMID: 20680154 PMCID: PMC2910951 DOI: 10.4103/0971-6866.55218
Source DB: PubMed Journal: Indian J Hum Genet ISSN: 1998-362X
Genotype frequencies of Hsp70-2 in control subjects and in patients with Kangri cancer
| Genotype | Kangri cancer (n=118) (f) | Control (n=95) (f) | Odd's ratio; χ2 |
|---|---|---|---|
| Hsp70-2 A/A | (10) 0.08 | (24) 0.25 | 0.273 (95% CI= 0.12-0.60); χ2 |
| Hsp70-2 A/G | (103) 0.88 | (70) 0.74 | 2.45 (95% CI= 1.20-4.98); χ2 |
| Hsp70-2 G/G | (5) 0.04 | (1) 0.01 | |
| A | 0.52 | 0.62 | 0.52 (95% CI= 0.35-0.78); χ2 |
| G | 0.48 | 0.38 | 1.505 (95% CI= 1.82-2.22); χ2 |
Hsp= Heat shock protein; f = genotype frequencies; χ2 = Chi-square; OR= odds ratio;
NS= Not significant; The Chi-square test was used whether significant differences (P-value) in genotype frequencies were observed when patient group was compared with control subject
Figure 1Restriction fragment length polymorphism analysis of Hsp70-2 gene: The Hsp70-2 PCR products(189bp) were digested with Pst1. The Hsp70-2A/Aallele corresponds to 116 and 73bp cleavage products (presence of Pst1 site) and hsp70-2G/G allele corresponds to 189bp uncleaved product (absence of Pst1 site). The reaction products electrophoresed on 3% agarose gel are shown. Lane#1: 50bp Molecular Weight Marker; Lane# 2, 4, 6: undigested HSP 70.2 189bp PCR product; Lane # 3, 5, 7 = Restriction enzyme Pst1 digested HSP 70.2 PCR product (all showing heterozygous change, hsp70-2A/G)
Genotype frequencies of Hsp70-hom in control subjects and in patients with Kangri cancer
| Genotype | Kangri cancer (n=118) (f) | Control (n=95) (f) | Odd's ratio; χ2 |
|---|---|---|---|
| Hsp70-2 C/C | (60)0.51 | (28)0.29 | 2.47(95% CI= 1.43-4.30); χ2 |
| Hsp70-2 C/G | (56)0.47 | (60)0.63 | 0.526(95% CI= 0.30-0.91); χ2 |
| Hsp70-2 G/G | (2)0.02 | (7)0.08 | |
| C | 0.74 | 0.61 | 1.87(95% CI= 1.23-2.82); χ2 |
| G | 0.26 | 0.39 | 0.53(95% CI= 0.35-0.80); χ2 |
Hsp= Heat shock protein; f = genotypefrequencies; χ2 = Chi-square; OR= odds ratio;
NS= Not significant; The Chi-square test was used whether significant differences (P-value) in genotype frequencies were observed when patient group was compared with control subjects
Figure 2Restriction fragment length polymorphism analysis of hsp70-hom gene: The hsp70-hom PCR products (878bp) were digested with Nco1. The hsp70-homC/C allele corresponds to 551bp and 327bp cleavage products (presence of Nco1 site) and hsp70-hom G/G allele corresponds to 878bp uncleaved product. The reaction products electrophoresed on 1.5% agarose gel are shown. Lane# 1: 100bp Molecular Marker; Lane# 2, 4, 6: undigested HSP70-hom 878bp PCR product; Lane# 3 & 7: Nco1 digested HSP70-hom PCR product (hsp70-homC/C allele); Lane# 5: Nco1 digested HSP70-hom PCR product (hsp70-hom C/G allele)
Association of high frequency Hsp70-2A/G or G/G and Hsp70-homC/C genotypes with various clinico-pathological features of Kangri cancer patients of Kashmir
| Features | Hsp70-2A/G or G/G | Hsp70-homC/C | ||
|---|---|---|---|---|
| Genotype (%) | Odd's ratio; χ2 | Genotype (%) | Odd's ratio; χ2 | |
| Age | 0.116(95%CI=0.02-0.48) χ2 | |||
| <50 | 23/30 (76.66) | 17/30 (56.66) | ||
| ≥ 50 | 85/88 (96.59) | 43/88 (48.86) | ||
| Clinical tumor stage | 3.8(95%CI=1.77-8.14)χ2 | |||
| T1 (a,b) | 50/60 (83.33) | 40/60 (66.66) | ||
| T2 (a,b) | 58/58 (100) | 20/58 (34.48) | ||
| Histopathological grading | 3.43(95%CI=1.59-7.41)χ2 | |||
| Grade I | 40/50 (80.00) | 34/50 (68.00) | ||
| Grade II | 68/68 (100) | 26/68 (38.23) | ||
| Lymph node status | 7.35(95%CI=1.77-30.52)χ2 | 0.06(95%CI=0.02-0.21)χ2 | ||
| N1 | 82/85 (96.47) | 31/85 (35.63) | ||
| N0 | 26/33 (78.78) | 29/33 (88.88) | ||
Hsp= Heat shock protein; f = genotype frequencies; χ2 = Chi–square; OR= odds ratio;
NS= Not Significant
NA = Not Applicable; The Chi-square test was used whether significant differences (P-value) in genotype frequencies were observed when patient group was compared with control subjects
Clinical tumor stage: T1 (a,b)= when tumor size ranges from >2 and >5 cm and metastasis to inguinal nodes but no metastasis, T2 (a,b)= tumor of any size, tumor extends to bone, any no of nodes involved and metastasis
Histopathological tumor grade (TNM classification): Determined based on pathological examination.
Lymph node status: N1= involved, N0= not involved